X4 Pharmaceuticals, Inc.
NASDAQ:XFORBiotechnology
+$0.06 today
- Market cap
- $304.30M
- Beta
- 0.37
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.79
Volume 0.64M
Average 0.40M
XFOR Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
X4 Pharmaceuticals, Inc.NASDAQ: XFOR
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 126.29M shares rose 1738.5% year over year, ahead of the +964.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 14.2% from the prior quarter. Over 3 fiscal years it compounded at +171.3% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1738.5% holds above the trailing-twelve-month pace of +964.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 42.29M USD
- Year-over-year change
- +531.0%
- 4-year CAGR
- +164.9%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.29M | +531.0% |
| FY2024 | 2024-12-31 | 6.7M | +13.1% |
| FY2023 | 2023-12-31 | 5.93M | +179.9% |
| FY2022 | 2022-12-31 | 2.12M | +146.7% |
| FY2021 | 2021-12-31 | 858.3K | — |
Weighted Avg Shares (Diluted) vs competitors
How XFOR compares with its peers on the latest reported figures
- XFOR's LTM Mar 2026 weighted avg shares (diluted) of 71.88M shares is the highest of the 4 companies compared; the peer median is 15M shares.
- Its year-over-year change of +964.0% is the highest of 4, against a peer median of +22.3%.
- Over three fiscal years its annual growth of +171.3% compares with a peer median of +14.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 71.88M | +964.0% | +171.3% | |
| LTM Mar 2026 | 25.76M | +22.3% | +14.0% | |
| LTM Mar 2026 | 15M | +69.0% | +26.1% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | 13.55M | +1.4% | +0.4% |
| Peer median (excluding XFOR) | 15M | +22.3% | +14.0% | |
Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2.56M | 35.11M |
| Cost of Revenue | 1.89M | 0 | 0 | 797K | 6.26M |
| Gross Profit | (1.89M) | 0 | 0 | 1.76M | 28.86M |
| Gross Margin | — | — | — | 68.8% | 82.2% |
| Research & Development | 48.76M | 61.06M | 72.02M | 81.64M | 72.22M |
| Selling, General & Admin | 24.7M | 27.02M | 35.51M | 61.52M | 43.52M |
| Operating Expenses | 73.46M | 87.57M | 107.52M | 38.16M | 115.74M |
| Depreciation & Amortization | 1.89M | 513K | 419K | 796K | 1.28M |
| EBITDA | (83.15M) | (89.33M) | (94.89M) | (27.58M) | (69.01M) |
| EBITDA Margin | — | — | — | -1078.5% | -196.5% |
| Operating Income | (75.35M) | (87.57M) | (107.52M) | (36.4M) | (86.88M) |
| Operating Margin | — | — | — | -1423.6% | -247.4% |
| Interest Income | 10K | 219K | 4.58M | 5.77M | 4.58M |
| Interest Expense | 3.64M | 3.99M | 5.78M | 8.77M | 8.88M |
| Other Income / Expenses | (13.33M) | (6.27M) | 6.43M | (739K) | 7.73M |
| Income Before Tax | (88.68M) | (93.84M) | (101.09M) | (37.14M) | (79.16M) |
| Pre-Tax Margin | — | — | — | -1452.5% | -225.4% |
| Income Tax Expense | 17K | 28K | 78K | 310K | 41K |
| Net Income | (88.7M) | (93.87M) | (101.17M) | (37.45M) | (79.2M) |
| Net Margin | — | — | — | -1464.6% | -225.6% |
| EPS (Basic) | (119.58) | (45.60) | (17.07) | (5.59) | (1.87) |
| EPS (Diluted) | (119.58) | (45.60) | (17.07) | (5.59) | (1.87) |
| Weighted Avg Shares | 858.3K | 2.12M | 5.93M | 6.7M | 42.29M |
| Weighted Avg Shares (Diluted) | 858.3K | 2.12M | 5.93M | 6.7M | 42.29M |
X4 Pharmaceuticals, Inc.
NASDAQ:XFOR
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.